Use your antibodies-online credentials, if available.
抗Human MED12 抗体:
抗Mouse (Murine) MED12 抗体:
抗Rat (Rattus) MED12 抗体:
Human Polyclonal MED12 Primary Antibody for ICC, IF - ABIN250749
Tutter, Kowalski, Baltus, Iourgenko, Labow, Li, Kadam: Role for Med12 in regulation of Nanog and Nanog target genes. in The Journal of biological chemistry 2009
Show all 11 Pubmed References
Human Polyclonal MED12 Primary Antibody for ELISA, WB - ABIN564287
Rienzo, Casamassimi, Schiano, Grimaldi, Infante, Napoli: Distinct alternative splicing patterns of mediator subunit genes during endothelial progenitor cell differentiation. in Biochimie 2012
Show all 2 Pubmed References
Human Polyclonal MED12 Primary Antibody for ICC, IF - ABIN4333402
Pérot, Croce, Ribeiro, Lagarde, Velasco, Neuville, Coindre, Stoeckle, Floquet, MacGrogan, Chibon: MED12 alterations in both human benign and malignant uterine soft tissue tumors. in PLoS ONE 2012
Study has shown that MED12 mutations can be heterogeneous in both synchronous and recurrent phyllodes tumor unlike TERT mutations. Authors have also shown that RBM15 mutations may be important in the pathogenesis of borderline/malignant phyllodes tumors.
data on MED12 mutation analyses (73.2% of tumors harbored a MED12 mutation) provide additional support for a significant role of MED12 in tumorigenesis
we aimed in this study to examine these common functional pathways in uterine leiomyomas (ULM)with different driver mutations. We collected ULM with MED12, HMGA2, and FH mutations and examined the selected markers by immunohistochemistry.
Here, we observed that overexpression of HMGA2 mRNA in tumors measured by quantitative PCR and compared to myometrium is a common phenomenon in fibroids and is frequently associated with MED12 mutations. In addition, the common clonal origin of tumors overexpressing HMGA2 mRNA and its expression in few myometrial tissue points to HMGA2 up-regulation as an early event in leiomyoma tumorigenesis.
Study confirmed the association of MED12 mutations with smaller leiomyoma size, multiplicity and conventional hystotype, and revealed novel associations between the MED12-mutation status and leiomyoma location and parity.
High frequency of the MED12 mutation in uterine leiomyomas of South Korean patients.
The high rate of TERT promoter mutations, MED12 mutations, RBM10 mutations, and chromosome 1q gain highlight their likely association with tumor virulence
Role of MED12 as a tumor suppressor in other cancers to include CRC, and suggest TGF-beta signaling as a potential mediator of this effect.
Hormonal status changing at various phases of menstrual cycle is a factor affecting DNA hydroxymethylation in leiomyoma cells.
High MED12 expression is associated with small cell lung cancer.
Data indicate that mediator complex subunit 12 (MED12) plays a central oncogenic role in breast fibroepithelial tumorigenesis.
MED12 mutation does not appear to represent a significant molecular alteration in this cohort of patients according to the analysis by the traditional "gold standard."
knockdown of MED12 was shown to confer resistance to apoptosis following pediatric T-cell acute lymphoblastic leukemia relevant chemotherapy drug treatment in Jurkat leukemia cells
Our findings provide new mechanistic insights into the MED12 functions and indicate that somatic nonsense mutations in early exons may avoid NMD.
With a strong genotype-phenotype correlation that is already known for MED12, this could be a new phenotype linked to MED12, thus expanding the phenotypic spectrum of MED12-related disorders.
The results suggest that MED12 mutations may contribute to chronic lymphocytic leukaemia pathogenesis by activating NOTCH signalling.
we investigated several MED12 patients mutations (p.R206Q, p.N898D, p.R961W, p.N1007S, p.R1148H, p.S1165P and p.R1295H) and show that each MED12 mutations cause specific expression patterns of JUN, FOS and EGR1 immediate early genes (IEGs), reflected by the presence or absence of MED12 containing complex at their respective promoters.
MED12 variants identified in males need to be evaluated carefully for these characteristics, as this severe phenotype may predict a potential risk for phenotypic expression in the heterozygotes. The identification of such a phenotype could influence the interpretation of future whole exome sequencing data and thus genetic counseling.
Current study findings may help to narrow down the number of MED12 mutations to be screened for mediator complex dysfunction associated genetic diseases. This study supports computational methods as a primary filter to verify the plausible impact of pathogenic mutations based on the perspective of evolution, expression and phenotype of proteins.
MED12-mutated adenosarcoma-like tumours might represent a distinct entity that requires more studies for its identification. MED12 exon 2 mutations seemed to have no significant role in other uncommon gynaecological mesenchymal tumours.
Med12 is critically important in reproductive tract development, and Med12 loss of function does not cause tumorigenesis in reproductive tissues.
Study provide evidence that Med12 regulates neural stem cell gene expression programs linked to adhesion and cell cycle progression but suppresses its adhesion by repressing the expression of cell adhesion molecules.
alterations in MED12-dependent enhancer regulation may control both physiological and malignant hematopoiesis.
The data reveal how the interplay between PRC1, ncRNA and Mediator complexes controls pluripotency and cellular differentiation.
Med1 and Med12, two subunits of the mediator complex implicated in transcription initiation and long-range enhancer/promoter loop formation, are dynamically recruited to the IgH locus enhancers.
leiomyomatous, Med12 c.131G>A variant-expressing uteri developed chromosomal rearrangements.
this work points to Med12 being an essential coregulator of transcription factors controlling neural tube closure.
show that in Med12 hypomorphic embryos, the Wnt/planar cell polarity pathway is disrupted and that canonical Wnt/beta-catenin signaling is impaired.
Nanog and Med12 function in concert to regulate Nanog target genes and identify a novel role for Med12 in embryonic stem cell regulation.
med12 mutants exhibit multiple defects in the development of the epithalamus, including failure of parapineal specification and disruption of cell differentiation and/or maintenance of specific cell types in the pineal organ and the habenula.
Mediator subunit 12 is required for neutrophil development in zebrafish.
The kto/med12 mutation results in specific defects of boundary cell formation in the zebrafish hindbrain
critical targets of TRAP230 function may include proteins important for cell mobility, cell sorting, and tissue assembly
A critical function of the Trap230 subunit is shown for Sox9 as a coactivator; Trap230 also participates in Sox9-independent transcriptional regulation.
reveal a regulatory role of motionless/Med12 in vertebrate neuronal development
Med12 modulates the ability of Casanova/Sox32 to induce sox17 expression in endodermal development.
The initiation of transcription is controlled in part by a large protein assembly known as the preinitiation complex. A component of this preinitiation complex is a 1.2 MDa protein aggregate called Mediator. This Mediator component binds with a CDK8 subcomplex which contains the protein encoded by this gene, mediator complex subunit 12 (MED12), along with MED13, CDK8 kinase, and cyclin C. The CDK8 subcomplex modulates Mediator-polymerase II interactions and thereby regulates transcription initiation and reinitation rates. The MED12 protein is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome.
CAG repeat protein 45
, OPA-containing protein
, activator-recruited cofactor 240 kDa component
, human opposite paired
, mediator of RNA polymerase II transcription subunit 12
, mediator of RNA polymerase II transcription, subunit 12 homolog
, putative mediator subunit 12
, thyroid hormone receptor-associated protein complex 230 kDa component
, thyroid hormone receptor-associated protein, 230 kDa subunit
, trinucleotide repeat containing 11 (THR-associated protein, 230 kDa subunit)
, trinucleotide repeat-containing gene 11 protein
, trinucleotide repeat containing 11
, OPA-containing protein 1
, mediator complex subunit 12
, trinucleotide repeat containing 11 (THR-associated protein)
, protein kohtalo
, protein motionless
, thyroid hormone receptor-associated protein 230
, thyroid hormone receptor-associated protein complex component TRAP230